Immuno-electronmicroscopy of fimbriae-like structures on Bordetella pertussis serotype 1.3

Fredriksen, J. H.; Frøholm, L. O.

doi:10.1099/00222615-25-4-285

Cited by 4 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The nature of agglutinogen 3 is less certain. Some studies (1,6) indicate that agglutinogen 3 is likely to be fimbrial, whereas Preston et ul. (14) in a recent study describe it as a non-fimbrial outer membrane protein.…”

Section: Discussionmentioning

confidence: 99%

Immunoelectron microscopy of antigens of Bordetella pertussis using monoclonal antibodies to agglutinogens 2 and 3, filamentous haemagglutinin, pertussis toxin, pertactin and adenylate cyclase toxin

Blom

Heron

Hendley

1994

APMIS

View full text Add to dashboard Cite

Immunogold electron microscopy and monoclonal antibodies (Mabs) were used to localize surface‐related antigens of Bordetella pertussis. Unfixed organisms of B. pertussis strains which are included in the Danish whole‐cell pertussis vaccine and fixed cells from a vial of vaccine were examined. Mabs to agglutinogens 2 and 3 labelled fimbria‐like structures on both live and fixed cells in a serotype‐specific manner. Mab against pertactin, a 69 kDa outer membrane protein, produced intense labelling of the surface of unfixed cells, whereas staining was reduced when fixed cells were examined. Mabs against filamentous haemagglutinin (FHA) stained aggregates of material between or adherent to both live and fixed cells. Negligible labelling of FHA on cell surfaces was observed. Mabs to pertussis toxin and adenylate cyclase toxin labelled loose‐structured material which was adherent to or between cells, but neither of these toxin antigens was expressed on the surface of B. pertussis in Mab recognizable form. It is therefore suggested that these antigens are readily dispersed after exit from the outer membrane of B. pertussis.

show abstract

Section: Discussionmentioning

confidence: 99%

Immunoelectron microscopy of antigens of Bordetella pertussis using monoclonal antibodies to agglutinogens 2 and 3, filamentous haemagglutinin, pertussis toxin, pertactin and adenylate cyclase toxin

Blom

Heron

Hendley

1994

APMIS

View full text Add to dashboard Cite

show abstract

“…Anti-PT responses are recommended to be documented as per WHO technical recommendations for wP vaccines [30]. In addition, B. pertussis agglutination assay has been the gold standard assay to assess wP vaccines responses in the past, and it has been described that most of the B. pertussis agglutinating activities measured in sera of wP-vaccinated subjects are mediated by anti-FIM antibodies [31][32][33][34]. Based on this, WHO recommends that wP vaccines must contain FIM2 and FIM3 antigens [30].…”

mentioning

confidence: 99%

Safety and immunogenicity of a new formulation of a pentavalent DTwP-HepB-Hib vaccine in healthy Indian infants–A randomized study

et al. 2023

View full text Add to dashboard Cite

Background Pentavalent vaccines (DTP-HepB-Hib) have been introduced in many countries in their routine public immunization programmes to protect against diphtheria (D), tetanus (T), pertussis (P), hepatitis B (Hep B) and Hemophilus influenzae type b (Hib) diseases. This study compared the safety and immunogenicity of a new formulation of a whole-cell Bordetella pertussis (wP) based pentavalent vaccine (DTwP-HepB-Hib). The new formulation was developed using well-characterized hepatitis B and pertussis whole cell vaccine components. Methods This was a phase III, observer-blind, randomized, non-inferiority, multi-center study conducted in India among 460 infants who were followed up for safety and immunogenicity for 28 days after administration of three doses of either investigational or licensed comparator formulations at 6–8, 10–12 and 14–16 weeks of age. Results The investigational formulation of DTwP-HepB-Hib vaccine was non-inferior to the licensed formulation in terms of hepatitis B seroprotection rate (% of subjects with HepB antibodies ≥10mIU/mL were 99.1% versus 99.0%, respectively, corresponding to a difference of 0.1% (95% CI, -2.47 to 2.68)) and pertussis immune responses (adjusted geometric mean concentrations of antibodies for anti-PT were 76.7 EU/mL versus 63.3 EU/mL, with a ratio of aGMTs of 1.21 (95% CI, 0.89–1.64), and for anti-FIM were 1079 EU/mL versus 1129 EU/mL, with a ratio of aGMTs of 0.95 (95% CI, 0.73–1.24), respectively). The immune responses to other valences (D, T, and Hib) in the two formulations were also similar. The safety profile of both formulations was found to be similar and were well tolerated. Conclusions The investigational DTwP-HepB-Hib vaccine formulation was immunogenic and well-tolerated when administered as three dose primary series in infants. Clinical trial registration Clinical Trials Registry India number: CTRI/2018/12/016692.

show abstract

Serospecific protection of mice against intranasal infection with Bordetella pertussis

Robinson

Gorringe

Funnell

et al. 1989

Vaccine

View full text Add to dashboard Cite

Immuno-electronmicroscopy of fimbriae-like structures on Bordetella pertussis serotype 1.3

Cited by 4 publications

References 10 publications

Immunoelectron microscopy of antigens of Bordetella pertussis using monoclonal antibodies to agglutinogens 2 and 3, filamentous haemagglutinin, pertussis toxin, pertactin and adenylate cyclase toxin

Immunoelectron microscopy of antigens of Bordetella pertussis using monoclonal antibodies to agglutinogens 2 and 3, filamentous haemagglutinin, pertussis toxin, pertactin and adenylate cyclase toxin

Safety and immunogenicity of a new formulation of a pentavalent DTwP-HepB-Hib vaccine in healthy Indian infants–A randomized study

Serospecific protection of mice against intranasal infection with Bordetella pertussis

Contact Info

Product

Resources

About